Trial Profile
Phase I Study of Cellular ImmunoTx Using Memory Enriched T Cells Lentivirally Transduced to Express an IL13Rα2-Specific, Hinge-Optimized, 41BB-Costimulatory Chimeric Receptor and a Truncated CD19 for Pts With Rec/Ref MaligGlioma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs MB 101 (Primary) ; MB 101 (Primary)
- Indications Brain cancer; Glioblastoma; Glioma
- Focus Adverse reactions
- 07 Mar 2024 According to a Mustang Bio media release, data from this study were published in Nature Medicine.
- 07 Mar 2024 Results published in a Mustang Bio Media Release.
- 03 Jul 2023 Planned End Date changed from 18 Jun 2023 to 18 Dec 2023.